The serum AST-to-ALT ratio serves as a proxy measure for NAFLD and was shown to be inversely associated with metabolic syndrome and insulin resistance in clinical and epidemiological studies [9, 21, 22]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.